Review of pyronaridine anti-malarial properties and product characteristics

• Published in: Malaria Journal
• Main Authors: Croft Simon L, Duparc Stephan, Arbe-Barnes Sarah J, Craft J, Shin Chang-Sik, Fleckenstein Lawrence, Borghini-Fuhrer Isabelle, Rim Han-Jong
• Format: Article in Journal/Newspaper
• Language: English
• Published: BMC 2012
• Subjects: Pyronaridine; Plasmodium falciparum; Plasmodium vivax; Review; Artemisinin containing compound; Anti-malarial therapy; Arctic medicine. Tropical medicine; RC955-962; Infectious and parasitic diseases; RC109-216; Arctic
• Online Access: https://doi.org/10.1186/1475-2875-11-270; https://doaj.org/article/e8f0fafc5209450f8248d7eb984813ff

Abstract Pyronaridine was synthesized in 1970 at the Institute of Chinese Parasitic Disease and has been used in China for over 30 years for the treatment of malaria. Pyronaridine has high potency against Plasmodium falciparum , including chloroquine-resistant strains. Studies in various animal models have shown pyronaridine to be effective against strains resistant to other anti-malarials, including chloroquine. Resistance to pyronaridine appears to emerge slowly and is further retarded when pyronaridine is used in combination with other anti-malarials, in particular, artesunate. Pyronaridine toxicity is generally less than that of chloroquine, though evidence of embryotoxicity in rodents suggests use with caution in pregnancy. Clinical pharmacokinetic data for pyronaridine indicates an elimination T 1/2 of 13.2 and 9.6 days, respectively, in adults and children with acute uncomplicated falciparum and vivax malaria in artemisinin-combination therapy. Clinical data for mono or combined pyronaridine therapy show excellent anti-malarial effects against P. falciparum and studies of combination therapy also show promise against Plasmodium vivax . Pyronaridine has been developed as a fixed dose combination therapy, in a 3:1 ratio, with artesunate for the treatment of acute uncomplicated P. falciparum malaria and blood stage P. vivax malaria with the name of Pyramax® and has received Positive Opinion by European Medicines Agency under the Article 58 procedure.